| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,
* Division of Infectious Diseases and AIDS Institute, University of California, Los Angeles Medical Center, Los Angeles, CA 90095;
Howard Hughes Medical Institute, Partners AIDS Research Center and Infectious Disease Division, Massachusetts General Hospital and Division of AIDS, Harvard Medical School, Boston, MA 02115; and
New England Regional Primate Center and Division of AIDS, Harvard Medical School, Southborough, MA 01772
Although CD8+ CTLs are presumed to be an important mediator of protective immunity in HIV-1 infection, the factors that determine CTL antiviral efficiency are poorly understood. Two factors that have been proposed to influence CTL antiviral function are antigenic avidity and epitope specificity. In this study we evaluate these by examining the activity of HIV-1-specific CTL against acutely infected cells. The ability of CTL to kill infected cells is variable and depends more on epitope specificity than functional avidity within the range for the tested clones (50% of maximal killing, 50 pg/ml to 100 ng/ml); killing efficiency is similar for different clones recognizing the same epitope, despite their variation in avidity. When CTL clones are tested for their ability to suppress viral replication, similar results are observed. Inhibition is more dependent on epitope specificity than functional avidity among the tested clones (50% of maximal killing, 20 pg/ml to 20 ng/ml). Thus, CTL specificity can be an overriding factor in the ability of CTL to interact with HIV-1-infected cells, indicating that factors determining the process of epitope presentation on infected cells have a key influence on CTL efficiency. These results suggest that CTL specificity may have a pivotal role in the immunopathogenesis of infection, and that simple quantitative measures of CTL may be insufficient indicators of the CTL response to HIV-1.
This article has been cited by other articles:
|
|
 |
|
  B. C. Simons, S. E. VanCompernolle, R. M. Smith, J. Wei, L. Barnett, S. L. Lorey, D. Meyer-Olson, and S. A. Kalams Despite Biased TRBV Gene Usage against a Dominant HLA B57-Restricted Epitope, TCR Diversity Can Provide Recognition of Circulating Epitope Variants J. Immunol., October 1, 2008; 181(7): 5137 - 5146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. L. Tagmyer, J. K. Craigo, S. J. Cook, D. L. Even, C. J. Issel, and R. C. Montelaro Envelope Determinants of Equine Infectious Anemia Virus Vaccine Protection and the Effects of Sequence Variation on Immune Recognition J. Virol., April 15, 2008; 82(8): 4052 - 4063. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Giraldo-Vela, R. Rudersdorf, C. Chung, Y. Qi, L. T. Wallace, B. Bimber, G. J. Borchardt, D. L. Fisk, C. E. Glidden, J. T. Loffredo, et al. The Major Histocompatibility Complex Class II Alleles Mamu-DRB1*1003 and -DRB1*0306 Are Enriched in a Cohort of Simian Immunodeficiency Virus-Infected Rhesus Macaque Elite Controllers J. Virol., January 15, 2008; 82(2): 859 - 870. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Liu, J. McNevin, H. Zhao, D. M. Tebit, R. M. Troyer, M. McSweyn, A. K. Ghosh, D. Shriner, E. J. Arts, M. J. McElrath, et al. Evolution of Human Immunodeficiency Virus Type 1 Cytotoxic T-Lymphocyte Epitopes: Fitness-Balanced Escape J. Virol., November 15, 2007; 81(22): 12179 - 12188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Sacha, C. Chung, J. Reed, A. K. Jonas, A. T. Bean, S. P. Spencer, W. Lee, L. Vojnov, R. Rudersdorf, T. C. Friedrich, et al. Pol-Specific CD8+ T Cells Recognize Simian Immunodeficiency Virus-Infected Cells Prior to Nef-Mediated Major Histocompatibility Complex Class I Downregulation J. Virol., November 1, 2007; 81(21): 11703 - 11712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Yang, T. Dong, E. Turnbull, S. Ranasinghe, B. Ondondo, N. Goonetilleke, N. Winstone, K. di Gleria, P. Bowness, C. Conlon, et al. Broad TCR Usage in Functional HIV-1-Specific CD8+ T Cell Expansions Driven by Vaccination during Highly Active Antiretroviral Therapy J. Immunol., July 1, 2007; 179(1): 597 - 606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Connick, T. Mattila, J. M. Folkvord, R. Schlichtemeier, A. L. Meditz, M. G. Ray, M. D. McCarter, S. MaWhinney, A. Hage, C. White, et al. CTL Fail to Accumulate at Sites of HIV-1 Replication in Lymphoid Tissue J. Immunol., June 1, 2007; 178(11): 6975 - 6983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Loffredo, B. J. Burwitz, E. G. Rakasz, S. P. Spencer, J. J. Stephany, J. P. Giraldo Vela, S. R. Martin, J. Reed, S. M. Piaskowski, J. Furlott, et al. The Antiviral Efficacy of Simian Immunodeficiency Virus-Specific CD8+ T Cells Is Unrelated to Epitope Specificity and Is Abrogated by Viral Escape J. Virol., March 15, 2007; 81(6): 2624 - 2634. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Sacha, C. Chung, E. G. Rakasz, S. P. Spencer, A. K. Jonas, A. T. Bean, W. Lee, B. J. Burwitz, J. J. Stephany, J. T. Loffredo, et al. Gag-Specific CD8+ T Lymphocytes Recognize Infected Cells before AIDS-Virus Integration and Viral Protein Expression J. Immunol., March 1, 2007; 178(5): 2746 - 2754. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Chung, W. Lee, J. T. Loffredo, B. Burwitz, T. C. Friedrich, J. P. Giraldo Vela, G. Napoe, E. G. Rakasz, N. A. Wilson, D. B. Allison, et al. Not All Cytokine-Producing CD8+ T Cells Suppress Simian Immunodeficiency Virus Replication J. Virol., February 1, 2007; 81(3): 1517 - 1523. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Wiseman, J. A. Wojcechowskyj, J. M. Greene, A. J. Blasky, T. Gopon, T. Soma, T. C. Friedrich, S. L. O'Connor, and D. H. O'Connor Simian Immunodeficiency Virus SIVmac239 Infection of Major Histocompatibility Complex-Identical Cynomolgus Macaques from Mauritius J. Virol., January 1, 2007; 81(1): 349 - 361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. Wilson, J. Reed, G. S. Napoe, S. Piaskowski, A. Szymanski, J. Furlott, E. J. Gonzalez, L. J. Yant, N. J. Maness, G. E. May, et al. Vaccine-Induced Cellular Immune Responses Reduce Plasma Viral Concentrations after Repeated Low-Dose Challenge with Pathogenic Simian Immunodeficiency Virus SIVmac239. J. Virol., June 1, 2006; 80(12): 5875 - 5885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. M. Boon, G. de Mutsert, R. A. M. Fouchier, A. D. M. E. Osterhaus, and G. F. Rimmelzwaan The Hypervariable Immunodominant NP418-426 Epitope from the Influenza A Virus Nucleoprotein Is Recognized by Cytotoxic T Lymphocytes with High Functional Avidity. J. Virol., June 1, 2006; 80(12): 6024 - 6032. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kan-Mitchell, M. Bajcz, K. L. Schaubert, D. A. Price, J. M. Brenchley, T. E. Asher, D. C. Douek, H. L. Ng, O. O. Yang, C. R. Rinaldo Jr., et al. Degeneracy and Repertoire of the Human HIV-1 Gag p1777-85 CTL Response. J. Immunol., June 1, 2006; 176(11): 6690 - 6701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Loffredo, E. G. Rakasz, J. P. Giraldo, S. P. Spencer, K. K. Grafton, S. R. Martin, G. Napoe, L. J. Yant, N. A. Wilson, and D. I. Watkins Tat28-35SL8-Specific CD8+ T Lymphocytes Are More Effective than Gag181-189CM9-Specific CD8+ T Lymphocytes at Suppressing Simian Immunodeficiency Virus Replication in a Functional In Vitro Assay J. Virol., December 1, 2005; 79(23): 14986 - 14991. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. D. Wick, O. O. Yang, L. Corey, and S. G. Self How Many Human Immunodeficiency Virus Type 1-Infected Target Cells Can a Cytotoxic T-Lymphocyte Kill? J. Virol., November 1, 2005; 79(21): 13579 - 13586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Chen, L. Wang, J. Zhang, L. Zou, Z. Jia, W. Zhou, Y. Wan, and Y. Wu H-2 Kd-Restricted Hepatitis B Virus-Derived Epitope Whose Specific CD8+ T Lymphocytes Can Produce Gamma Interferon without Cytotoxicity J. Virol., May 1, 2005; 79(9): 5568 - 5576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Asquith, A. J. Mosley, A. Barfield, S. E. F. Marshall, A. Heaps, P. Goon, E. Hanon, Y. Tanaka, G. P. Taylor, and C. R. M. Bangham A functional CD8+ cell assay reveals individual variation in CD8+ cell antiviral efficacy and explains differences in human T-lymphotropic virus type 1 proviral load J. Gen. Virol., May 1, 2005; 86(5): 1515 - 1523. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Tomiyama, M. Fujiwara, S. Oka, and M. Takiguchi Cutting Edge: Epitope-Dependent Effect of Nef-Mediated HLA Class I Down-Regulation on Ability of HIV-1-Specific CTLs to Suppress HIV-1 Replication J. Immunol., January 1, 2005; 174(1): 36 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. A. Jones, X. Wei, D. R. Flower, M. Wong, F. Michor, M. S. Saag, B. H. Hahn, M. A. Nowak, G. M. Shaw, and P. Borrow Determinants of Human Immunodeficiency Virus Type 1 Escape from the Primary CD8+ Cytotoxic T Lymphocyte Response J. Exp. Med., November 15, 2004; 200(10): 1243 - 1256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Chen, K. Pang, K.-A. Masterman, G. Kennedy, S. Basta, N. Dimopoulos, F. Hornung, M. Smyth, J. R. Bennink, and J. W. Yewdell Reversal in the Immunodominance Hierarchy in Secondary CD8+ T Cell Responses to Influenza A Virus: Roles for Cross-Presentation and Lysis-Independent Immunodomination J. Immunol., October 15, 2004; 173(8): 5021 - 5027. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ali, R. Lubong, H. Ng, D. G. Brooks, J. A. Zack, and O. O. Yang Impacts of Epitope Expression Kinetics and Class I Downregulation on the Antiviral Activity of Human Immunodeficiency Virus Type 1-Specific Cytotoxic T Lymphocytes J. Virol., January 15, 2004; 78(2): 561 - 567. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
